On March 19, 2023 Triumvira Immunologics ("Triumvira"), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that the Company will be presenting preclinical and clinical data on its lead asset TAC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Orlando, April 14-19 (Press release, Triumvira Immunologics, MAR 19, 2023, View Source [SID1234629018]). The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 (NCT04727151) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present additional validation of our lead clinical program TAC01-HER2, currently in Phase I/II trials, supporting the efficiency of our proprietary Cocoon platform to manufacture potent autologous TAC01-HER2 cells using leukocytes from cancer patients," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics. "Interim results will also be presented from our ongoing Phase I/II trial investigating the safety and efficacy of autologous TAC01-HER2 in HER2+ refractory solid tumors demonstrating a favorable safety profile and promising clinical activity as evident by reduction of measurable disease and prevention of fast cancer progression in the majority of patients enrolled in the Phase I trial. Further, we will present new preclinical data from our allogeneic T cell-based products in development demonstrating their potential to avoid graft versus host disease."

On March 17, 2023 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") reported that its self-developed bispecific antibody-receptor recombinant protein drug targeting both CD47 and CD20 (project number: IMM0306) completed phase I dose escalation study and officially entered phase IIa clinical trial for third-line and above advanced follicular lymphoma (FL) (Press release, ImmuneOnco Biopharma, MAR 17, 2023, View Source [SID1234655686]). This is another milestone achievement for ImmuneOnco in its rapid development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Previously, IMM0306 has been approved by China’s NMPA and the US FDA for clinical trials and has been granted patents in China, the US, and Japan, consolidating ImmuneOnco Biopharmaceuticals‘ leading position in the development of CD47-targeted drugs and bispecific antibody research. Currently, the IMM0306 project has been selected by project experts to enter the IIa phase clinical trial with a single safe and effective dose of 2mg, targeting FL and marginal zone lymphoma (MZL) and other indolent lymphomas of third-line and above. Meanwhile, the Ib/IIa phase clinical trial of IMM0306 in combination with lenalidomide for second-line diffuse large B-cell lymphoma (DLBCL) and second-line follicular lymphoma is also underway.

The phase I clinical study of IMM0306 targeting relapsed or refractory B-cell lymphoma showed encouraging efficacy and good safety characteristics. From four different dose groups ranging from 0.8mg/kg to 2.0mg/kg, two cases of complete response and five cases of partial response have been observed, and it is encouraging that no significant cytokine storm toxicity has been observed in all patients.

Founder and Chairman of ImmuneOnco Biopharmaceuticals Dr. Wenzhi Tian stated: "I am thrilled to announce that our IMM0306 project has completed Phase I study and entered Phase IIa clinical trial for the treatment of relapsed/refractory follicular lymphoma (FL) of third line and beyond. IMM0306 is a first-in-class CD47xCD20 bispecific antibody-receptor fusion protein (mAb-Trap) targeting both CD47 and CD20, and is the first CD47xCD20 dual-targeting molecule entering clinical development globally. In vitro, IMM0306 does not bind to human red blood cells, and preclinical pharmacology studies showed that its efficacy at the equivalent dose was significantly better than rituximab. Phase I clinical data demonstrated good safety profile and promising clinical efficacy as a monotherapy, particularly in patients with relapsed/refractory FL, marginal zone lymphoma (MZL), and DLBCL. We will continue to advance the research of the IMM0306 project and aim to bring a new hope to cancer patients as soon as possible."

Chief Medical Officer/Senior Vice President of ImmuneOnco Biopharmaceuticals Dr. Qiying Lu stated: "Today, for our company, it is of great significance that IMM0306, one of our core products, has completed phase I dose escalation and smoothly entered phase IIa. Currently, outstanding efficacy has been observed in monotherapy for multiple indications, including indolent lymphomas such as FL and MZL, as well as the most common aggressive lymphoma in the clinic, DLBCL, indicating the broad clinical development prospects of this product. We have comprehensively planned the development of this product in multiple indications, which will fully reflect our differentiated layout. Not only in monotherapy, but we also plan to further develop it in combination with other standard treatments, including lenalidomide, for frontline lymphoma. The company will accelerate the clinical development of this product and look forward to bringing new choices for cancer treatment and meeting the clinical needs of unmet patients."

On March 17, 2023 Jacobio Pharmaceuticals reported the company has received IND (Investigational New Drug) approval of its self-developed drug GUE inhibitor JAB-24114 from the Center for Drug Evaluation (CDE) of China (Press release, Jacobio Pharmaceuticals, MAR 17, 2023, View Source [SID1234644981]). Jacobio plans to initiate a Phase I/IIa clinical trial in the China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways such as TCA cycles, nucleotide synthesis, purine synthesis and amino acid synthesis. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. Preclinical in vivo study exhibited that JAB-24114 can effectively inhibit tumor growth in multiple animal models.

JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors. Jacobio has self-developed SHP2 inhibitors (JAB-3312 and JAB-3068), KRAS G12C inhibitor Glecirasib (JAB-21822), and KRASmulti inhibitor (JAB-23400), which have potential to provide more combination therapies to patients.

Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one program in the Phase I clinical stage in respective drug class globally.

On March 17, 2023 Philogen reported that it has attend Stifel European Healthcare Summit in Bordeaux on June 28-30, 2023 (Press release, Philogen, MAR 17, 2023, View Source [SID1234629109]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event and will be available for 1o1 meetings with Investors.

On March 17, 2023 Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, reported that on March 16, 2023, the LA County Superior Court confirmed an arbitration award of $125 million in damages, to be paid by NantPharma, LLC ("NantPharma") (Press release, Sorrento Therapeutics, MAR 17, 2023, View Source [SID1234629048]). The award reflects the values of lost milestones for the approval of the drug Cynviloq for the treatment of breast and lung cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: "We are pleased that the Court has affirmed the result of the arbitration against NantPharma and has awarded $125 million in damages to Sorrento. From here, we remain focused on our important work of developing new and innovative therapies for patients struggling with cancer, intractable pain, infectious disease, and more."

The award stems from an arbitration between Sorrento and NantPharma regarding the development of chemotherapy drug Cynviloq, the rights to which NantPharma acquired from Sorrento in 2015. In 2019, Sorrento filed an arbitration demand against NantPharma, alleging that the company had failed to live up to its contractual obligations to develop Cynviloq and bring it to market.

On December 19, 2022, following nearly two years of discovery and an 18-day evidentiary hearing, the Honorable Faith Hochberg, whom the parties selected to preside over the Cynviloq Arbitration, awarded Sorrento $125 million in damages. On March 16, 2023, the LA County Superior Court granted Sorrento’s motion to confirm the award, which Sorrento now intends to enforce against NantPharma.